Introduction

Chronic Wounds
Impaired wound healing is a significant healthcare problem in the United States that affects more than 6.5 million people 1 . Patients with diabetes are ten times more likely to suffer amputation due to non-healing wounds, and the Center for Disease Control estimates that 1 in 3 of today's children will develop diabetes in their lifetime 2, 3 . It is anticipated that the prevalence of problematic skin wounds will parallel the expanding diabetes pandemic. Thus, there is an established, growing, and unmet clinical need for improved treatment of chronic wounds.
In normal wound healing, a coordinated combination of cellular infiltration, proliferation, and extracellular matrix deposition directs a transition from the initial inflammatory response at a site of injury to the process of tissue regeneration 4, 5 . Two cell types that are particularly relevant to this shift are fibroblasts and mesenchymal stem cells. Fibroblasts play a key role in wound remodeling via their proliferation, secretion of growth factors, extracellular matrix production, and promotion of angiogenesis 4 . However, fibroblasts isolated from chronic wounds show a decrease in proliferation rate and a diminished response to various cytokines 4, 6 . While the mechanism for this alteration in fibroblast behavior has not been identified, this indicates that mere delivery of growth factors will be insufficient to fully restore normal fibroblast behavior at the site of chronic wounds.
MSCs are central regulators of wound healing; they modulate the inflammatory response and release bioactive factors that influence the migration, proliferation, and phenotype of nearby cells. Additionally, the capacity of MSCs to differentiate into various tissue-forming cell types endows them with particular value in functional tissue regeneration 5 . Modulating the characteristics and activities of cells essential to the wound healing process, such as fibroblasts and MSCs, is a potentially high-impact strategy for chronic wound treatment.
Due to the complex nature of wound healing, a variety of physiological abnormalities can contribute to impaired healing. However, inadequate angiogenesis and the resulting deficiencies in oxygen and nutrient delivery to developing tissue have been identified as key problems in chronic wounds 4 . The inhibition of prolyl hydroxylase 2 (PHD2) in cells recruited to the site of wound healing has emerged as a powerful strategy to promote angiogenesis. PHD2 is an endogenous negative regulator of the transcription factor hypoxia-inducible factor-1α (HIF-1α) 7 .
Potent inhibition of PHD2 results in a large up-regulation of HIF-1α and its downstream genes VEGF, fibroblast growth factor 2 (FGF-2), endothelial nitric oxide synthase (eNOS), angiopoietin (ANGPT), and stromal cell-derived factor 1 (SDF-1) 8, 9 . These factors orchestrate both formation and maturation of vessels and, in the case of SDF-1, recruit endothelial progenitors that further promote local vasculogenesis 10 . This work aims to optimize a therapeutic strategy for PHD2 inhibition that will prompt angiogenesis in non-healing wounds and therefore promote wound resolution.
siRNA Therapeutics
Physiological gene inhibition presents a powerful alternative to typical small molecule drugs, as the suppression of a strategically selected gene allows for simultaneous modulation of a myriad of downstream targets and facilitates a broad and coordinated therapeutic effect. Small interfering RNA (siRNA) therapeutics are capable of potently and specifically silencing a gene of interest and therefore show great promise for treatment of a broad range of disease states, 3 including that of impaired wound healing. However, clinical application of siRNA remains limited by barriers to delivery to its site of action in the cellular cytoplasm. siRNA has a short half-life in vivo, is incapable of effectively translocating the cellular membrane, and faces lysosomal degradation upon endocytosis. Strategies to address these issues are diverse, encompassing a wide range of carriers and conjugates 11 . Most relevant to this work are methods that hydrophobize the siRNA delivery system, particularly via direct conjugation of a hydrophobic moiety.
The conventional and most utilized approach for delivery of siRNA is via electrostatic condensation into nanocarriers using polycationic polymers or lipids. Optimized polymeric and lipid carriers can protect the siRNA against degradation and transport it into the cell 12 . The incorporation of endosomolytic moieties like propyl(acrylic acid) can also facilitate endosomal escape 13 . However, these carrier systems can elicit an immune response and cytotoxicity at high concentrations 14 . Increasing gene silencing potency and enabling the use of lower doses of the delivery system thus enhances the likelihood of siRNA's therapeutic application. A promising strategy to accomplish this aim is via hydrophobization of the carrier or of the siRNA itself.
Increased hydrophobicity of cationic polymer siRNA delivery systems has been shown to correspond to improvements in gene silencing. Hydrophobization of the cationic carrier poly(ethylene imine) via conjugation of lipids to the polymer maintains silencing efficacy while reducing cytotoxicity, although the lipid chains begin to negatively impact gene silencing at a threshold chain length 15 . Additionally, more hydrophobic poly(β-amino ester)-based delivery vehicles were shown to achieve greater transfection than comparable counterparts 16 . Developing a balance between hydrophobic content and cationic content of an siRNA carrier could allow for enhanced uptake and silencing efficiency at a lower polymer dose 17 .
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Hydrophobization of the siRNA itself is another approach to facilitate increased interaction with the cellular membrane and thus improve uptake. Lipid-conjugated siRNA has been explored as a means of gene silencing both with and without an additional carrier 18, 19 . It was found that palmitic acid conferred increased stability to siRNA while also enhancing cellular penetration and gene silencing 20, 21 . Palmitic acid-conjugated siRNA (siRNA-PA) was additionally found to be superior to various aromatic groups and additional lipidic moieties in gene silencing efficacy and cellular internalization 22, 23 . While siRNA-PA exhibited some silencing activity without a carrier system, it was most efficacious in combination with the commercial lipidic vector Lipofectamine2000.
Approach
Our lab has previously reported on biomaterial scaffold-based delivery of siRNA-loaded endosomolytic polymer nanoparticles to promote angiogenesis at wound sites. The siRNA delivered was designed against PHD2 and promoted therapeutic neovascularization of ischemic tissues, enhanced tissue repair, and facilitated tissue scaffold vascularization and integration 24, 25 .
This work aims to optimize the design of the siRNA nanoparticle system and reduce the polymer dose required to elicit potent and sustained gene silencing. Our approach is to conjugate PA directly to siRNA, thereby improving its stability as well as increasing the hydrophobicity of the siRNA-loaded nanoparticles. It is anticipated that the conjugation of PA will broaden the therapeutic index of this carrier system and increase the likelihood of successful translation of this system in wound healing applications.
Introduction
Therapeutic application of RNA interference provides the potential to potently and specifically suppress transcription factors, subsets of kinases, and other signaling molecules that are traditionally considered "undruggable". Unfortunately, achieving successful in vivo delivery of siRNA has proven a complex and difficult challenge, impeding medicinal translation of siRNA therapeutics. siRNA has a short half-life due to nuclease susceptibility, rapid renal clearance if injected intravenously, and an inability to translocate the membranes that make up the outer cell surface and the vesicles of the endolysosomal recycling/degradation pathways 11, 26, 27 . Numerous and varied strategies have been developed in attempts to address these delivery obstacles, including modifications to the siRNA backbone, the use of lipids and polymers as carrier systems, and the conjugation of siRNA to cell-penetrating/cell-binding peptides, antibodies, dendrimers, and lipid-like molecules 11, 15, [28] [29] [30] [31] . Tremendous progress has been made, especially in the application of lipid nanoparticles for delivery of siRNA against hepatic targets, but widespread medicinal application of siRNA remains a distant goal 32, 33 . Thus, there is a continued need to better elucidate the ideal siRNA chemistry and its potential synergism with polymeric-and lipid-based carriers, with the goal of discovering combinations that will expand the therapeutic use of siRNA for a broader set of clinical indications.
Work from our lab and others has focused on diblock copolymers that can package and deliver siRNA to the cytoplasm, facilitated by pH-dependent membrane disruptive activity that promotes endosomal escape 17, 24, 29, 34 . In the current work, we sought to improve the performance of siRNA formulations with these promising polymers, with the goal of improving efficacy and longevity of action such that functional effects can be achieved at a reduced polymer/siRNA dose. Lessening the dose of the carrier is anticipated to be advantageous in 7 reducing nonspecific side effects, as high doses of both cationic lipids and polymers can induce production of inflammatory cytokines and interferons, global changes in gene expression, and toxicity 11, 14, 30, 35 .
Hydrophobization of nucleic acid delivery systems has been demonstrated to enhance carrier stability and transfection efficiency in a broadly applicable manner [15] [16] [17] 36 . The conjugation of hydrophobic moieties to siRNA can increase siRNA nuclease resistance and enhance cellular internalization without detrimentally impacting gene silencing activity 20, 23 .
Direct conjugation of siRNA to cholesterol and α-tocopherol improves gene silencing efficacy in vivo, especially when the target site is the liver and after incubation of the conjugated siRNA with lipoproteins 19, 37, 38 . Conjugation of palmitic acid (PA) to siRNA has shown particular promise as a modification strategy to improve siRNA stability, cellular penetration, and gene silencing 23 . PA is an endogenous post-transcriptional modification commonly found on membrane-associated signaling proteins. While PA is involved in a wide variety of cellular functions, it is especially believed to influence protein-membrane interactions as well as protein uptake and intracellular trafficking [39] [40] [41] . Motivated by the inherent effects of PA on membrane binding and translocation, PA-modified siRNA has been recently tested as an approach to enhance gene silencing in comparison to unmodified siRNA or siRNA conjugated to cholesterol in cancer cell lines in vitro 20, 23 . In these studies, PA conjugation was demonstrated to enhance knockdown of siRNA delivered via Lipofectamine 2000 (a commercial transfection reagent with established cytotoxicity) and also to enable some gene silencing in the absence of a transfection reagent at high (micromolar) doses 14, 20 .
These promising siRNA conjugate results motivated the current study, which was aimed at testing siRNA-PA conjugates for delivery via endosomolytic polymer-based nanoparticles and 8 at assessing PA conjugates in different cell lines relevant to regenerative medicine applications.
The ultimate goal of these studies is to enhance the therapeutic potency in order to minimize the quantity of polymeric carrier and siRNA required, thus reducing the potential for nonspecific effects. We have previously delivered polymeric siRNA nanoparticles from porous, biodegradable polyester urethane (PEUR) scaffolds to achieve tunable and potent gene silencing 24, 25 . This approach for local siRNA delivery has shown tremendous potential in applications for tissue regeneration, especially through local silencing of prolyl hydroxylase domain protein 2 (PHD2) to promote wound healing. PHD2 negatively regulates hypoxia inducible factor 1α, a pro-angiogenic transcription factor, and scaffold-based delivery of PHD2
siRNA activates a pro-angiogenic, pro-proliferation program 25, 42, 43 . The current studies were designed to assess the potential of PA conjugation for enhancing the potency and longevity of gene silencing of siRNA for ultimate application in wound healing. and mouse marrow stromal cells (C57Bl/6-TgNs) were purchased from Jackson Laboratory (Bar Harbor, ME). Propylacrylic acid was synthesized as previously reported 1, 2 . All other reagents were purchased from Sigma-Aldrich (St. Louis, MO).
Experimental Methods
Materials
Oligonucleotide-PA Synthesis and Characterization: Single-stranded amine-modified oligo was reacted with 100-fold molar excess of PA N-hydroxysuccinimide ester pre-dissolved at 40 mM in N,N-dimethylformamide (DMF). The reaction was carried out for 18 hours at room temperature in 45% water, 45% isopropyl alcohol, and 10% DMF. The oligo-PA was purified by reversed-phase HPLC using a Clarity Oligo-RP column (Phenomenex, Torrence, CA) under a linear gradient from 95% water (50 mM triethylammonium acetate), 5% methanol to 100%
methanol. The conjugate molecular weight was confirmed using MALDI-TOF mass spectrometry (Voyager-DE STR Workstation, Grand Island, NY) using 50 mg/mL 3-hydroxypicolinic acid in 50% water, 50% acetonitrile with 5 mg/mL ammonium citrate as a matrix. The yield of the oligo-PA was quantified based on absorbance at 260 nm. The purified oligo-PA was annealed to its complementary strand to generate Cy5-modified DNA-PA or siRNA-PA. Conjugation and annealing was also confirmed via agarose gel electrophoresis.
Oligonucleotide-loaded Nanoparticle (NP) Synthesis and Characterization: A diblock copolymer composed of a homopolymer of 2-(dimethylamino) ethyl methacrylate (DMAEMA)
blocked with a random copolymer of DMAEMA, 2-propylacrylic acid (PAA), and butyl methacrylate (BMA) was synthesized using reversible addition-fragmentation chain transfer (RAFT) polymerization as described previously 24, 29 Gel electrophoresis was used to test loading efficiency at varied amine:phosphate (N:P) ratios. A red blood cell hemolysis assay 44 was used to determine pH-dependent membrane disruptive activity of oligo NPs as a marker for endosomal escape functionality. Luciferase Silencing: NIH-3T3s or mMSCs were treated with siRNA NPs or siRNA-PA NPs;
Production of Stable
the siRNA was either designed against the luciferase gene (luc siRNA) or was a scrambled sequence (scr siRNA). Cells were treated in 10% serum for 24 hours before imaging with an IVIS 200 imaging system (Caliper Life Sciences, Hopkinton, Massachusetts). Unless otherwise noted, an N:P ratio of 4:1 was used. In the investigation on longevity of luciferase silencing, the media was changed after 12 hours of treatment to 2% serum to prevent cellular overgrowth.
PHD2
Gene Silencing: NIH-3T3s were treated with siRNA NPs or siRNA-PA NPs at an N:P ratio of 4:1 as described above except for using prolyl-hydroxylase 2 (PHD2) siRNA. Cells were treated in 10% serum for 24 hours and then incubated for 24 hours, and the degree of PHD2 knockdown was quantified by real time polymerase chain reaction (RT-PCR) using the ΔΔCt method and normalizing to glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Cellular Uptake and Retention: NIH-3T3s were treated with Cy5-labeled DNA NPs or DNA-PA NPs in 10% serum for 12 hours at 12.5 nM. To measure retention with minimal dilution effects due to cell proliferation, media was then changed to 2% serum, and cells were cultured for up to an additional 72 hours. Intracellular fluorescence was quantified using flow cytometry at 12, 36, 60, and 84 hours. Extracellular membrane-bound fluorescence was quenched with
Trypan Blue. For confocal microscopy imaging studies, NIH-3T3s were treated with 25 nM
Cy5-labeled DNA NPs or DNA-PA NPs in 10% serum for 12 hours before media was changed to 2% serum. Cell nuclei were stained with DAPI (using NucBlue Fixed Cell ReadyProbes), and cellular fluorescence was imaged using confocal microscopy at 12, 36, and 60 hours.
To assess the mechanism of uptake of PA-conjugated oligo NPs, NIH-3T3s were pre- Gene Silencing Efficacy of siRNA-PA NPs: The influence of the difference in loading efficiency (i.e., N:P ratio required for full packaging) between unmodified and PA-modified siRNA was also investigated for gene silencing. While luc NPs showed a significant increase in luciferase silencing between a ratio of 4:1 and 6:1, no difference was seen in luc-PA NPs between these two different N:P ratios (Figure 4 ). Greater cytotoxicity, as evaluated by the scrambled controls, was seen at 6:1 in comparison to 4:1 demonstrating the impact of achieving more efficient loading and activity with a smaller quantity of polymeric carrier ( Figure S2 ).
Superior silencing was detected for luc-PA NPs in comparison to luc NPs at all N:P ratios.
At a fixed N:P ratio of 4:1, increased gene silencing bioactivity of luc-PA NPs over luc NPs was apparent in both mouse fibroblasts (NIH-3T3s) and mMSCs ( Figure 5 ). The IC 50 was 14 calculated based on equation 1 where y is the fraction luciferase activity, x is the concentration in nM, and b is a fit parameter.
Equation 1:
The IC 50 of luc-PA NPs was 2.2-fold and 3.1-fold lower than that of luc NPs in the fibroblasts and the mMSCs, respectively, indicating that siRNA conjugation to PA significantly improves the gene silencing potency for a given N:P ratio. No significant difference in cytotoxicity was seen in the scr NPs compared to the scr-PA NPs. No significant cytotoxicity was seen below a 40 nM dose of siRNA NPs in the fibroblasts, and no significant cytotoxicity was seen at any of the siRNA NP doses tested in the mMSCs. No cytotoxicity was detected for any siRNA-PA NP doses tested in the fibroblasts or mMSCs. The impact of PA modification on efficiency of silencing of the therapeutically-relevant gene PHD2 was also investigated. PHD2-PA NPs significantly enhanced gene silencing in comparison to PHD2 NPs when evaluated by RT-PCR ( Figure 6 ). In fibroblasts, the IC 50 of PHD2-PA NPs was 2.3-fold lower than that of PHD2 NPs. These data agree well with the data acquired using luc siRNA, confirming that the bioactivity gained through PA conjugation is consistent across different siRNAs. Next uptake pathway inhibitors were used to investigate the uptake mechanism of DNA-PA NPs in fibroblasts. EIPA, an amiloride analog and inhibitor of macropinocytosis, and cytochalasin D, which disrupts actin filament formation and thus impedes both caveolaemediated uptake and macropinocytosis, significantly inhibited uptake of the DNA-PA NPs (Figure 8) . Dynasore, which blocks a dynamin GTPase necessary for formation of all clathrincoated vesicles and for uptake through caveolae, had no effect on uptake of DNA-PA NPs. 
Discussion
Direct conjugation of siRNA to targeting ligands, lipophilic moieties, or carrier molecules is a promising approach to enhancing knockdown efficacy and/or reducing the need for additional transfection reagents 38, 45, 46 . Palmitic acid has shown particular promise for increasing resistance to nuclease degradation, cellular uptake, and gene silencing in initial in vitro tests using commercial lipid-based reagents 23 . Herein, we have characterized the performance of siRNA-PA relative to unmodified siRNA delivered via endosomolytic, polymer-based NPs that have previously demonstrated efficacy both in vitro and for local scaffold-based delivery in vivo 25, 29 .
The goal was to improve the potency and longevity of action of the siRNA and to reduce the potential for negative side effects in ultimate scaffold-based siRNA-NP delivery applications.
The siRNA-PA was successfully synthesized using a one-step reaction and purified using HPLC ( Figure 1 ). An important advantage of siRNA-PA over unmodified siRNA was its improved NP packaging. siRNA-PA completely loaded into the NPs at a 4:1 N:P ratio, while unmodified siRNA necessitated a 6:1 ratio for the polymer utilized in these studies ( Figure 2 ).
These data suggest that hydrophobization of siRNA is an efficient means to improve siRNA cargo loading and stability of NPs 36 . Other reports that nanoparticle carriers loaded with lipidmodified siRNA form particles at lower N:P ratios and with increased stability also support this conclusion 45, 47, 48 . It is posited that interactions among siRNA molecules through the lipophilic moieties increase negative charge density by localizing multiple siRNA molecules; this grouping is proposed to improve loading by cationic agents 45, 49 . Additionally, aggregated lipophilic moieties contribute to micelle stability 48 . Another potential contributing factor, in our NP carriers in particular, is that the PA molecule may help to anchor the siRNA into the hydrophobic micellar nanoparticle core. These hydrophobic interactions could help to reinforce the electrostatic interactions between the siRNA and the poly(DMAEMA)-based NP corona. This hypothesis is supported by the finding that siRNA-PA NPs had larger hydrodynamic diameter than siRNA NPs (Figure 3 ), while unloaded NPs and siRNA NPs were the same size (data not shown). These data suggest that siRNA-PA impacts the overall NP packing, potentially due to increased interaction with the NP core.
Next, siRNA-PA NP silencing of both the model gene luciferase and of the therapeutically relevant gene PHD2 was benchmarked against siRNA NPs in fibroblasts. Similar studies were also done in MSCs, which have relevance for tissue regenerative applications and represent a cell type that is notoriously challenging to transfect 31, 50 . The first study assessed the effects of the N:P ratio used in the NP formulation on luciferase silencing in fibroblasts. At every Achieving potent silencing with a lower N:P is key to minimizing detrimental treatment effects, as a charge ratio of 6:1 began to cause increased cytoxicity in fibroblasts ( Figure S2 ). The siRNA-PA NPs achieved a high level (more than 70%) of silencing efficacy even at an N:P of 1:1, which was superior to unmodified siRNA loaded at a 4:1 N:P ratio (the standard formulation condition for this polymeric NP composition) 24, 29 .
Gene silencing potency was also compared for the siRNA-PA NPs and unmodified siRNA NPs formed at a constant N:P of 4:1. In fibroblasts, the dose of siRNA-PA NPs required to achieve 50% gene silencing was consistently two-to three-fold lower than the dose of siRNA NPs needed to achieve this effect. The improved potency of siRNA-PA NPs was apparent both for the model gene luciferase and for the therapeutically-relevant gene PHD2 ( Figure 5A, 6 ). An even greater increase in gene silencing potency of more than three-fold was observed in MSCs (
Figure 5B 40 .
Unlike strategies to increase bioactivity by increasing the polymer:siRNA N:P ratio, the siRNA conjugated to PA did not have any impact on cell viability. Because the siRNA-PA conjugation decreases the amount of polymer needed and also increases the relative potency of the siRNA, it has the potential to strongly impact the therapeutic index for polymeric NP siRNA formulations.
In order to better understand the mechanism for the improved gene silencing performance of siRNA-PA NPs, cellular uptake and intracellular retention were measured by flow cytometry.
The results revealed a 35-fold increase in cellular uptake of DNA-PA NPs relative to DNA NPs in fibroblasts. This effect is attributable to the presence of PA moieties, which may hydrophobically interact with cell membranes. Endogenous PA modification of proteins facilitates membrane binding and endocytotic processes 39, 41 , and the number of lipophilic modifications on nucleic acids directly correlates to the level of association with cell membranes 49 . Therefore, the presence of multiple PA moieties on the corona of the NPs may act cooperatively to facilitate uptake, in combination with the positive zeta potential of the NPs.
Previous studies of PA-modified siRNA employing Lipofectamine 2000 as a delivery agent showed more modest improvements in cellular uptake relative to the gains achieved herein with polymeric NPs 20 . This discrepancy is likely attributable to differences in the mechanism of siRNA complexation or cellular internalization achieved with each type of reagent. For example, cholesterol-modified siRNA loaded into cationic polymer micelles also demonstrated moderate cellular uptake enhancement over unmodified siRNA in comparison to the improvement with 24 siRNA-PA over siRNA in our system 47 . However, in this system, lipophilic siRNA was packaged in the core of the micelles, whereas our NP carriers load siRNA/siRNA-PA onto the micelleplex corona, potentially promoting multivalent PA interactions with the cell membrane.
Investigation into the uptake mechanism of PA-conjugated oligo NPs revealed a larger role for macropinocytotic uptake in comparison to clathrin and caveolin-mediated endocytosis, as seen by the lack of uptake inhibition by Dynasore in comparison to EIPA and cytochalasin D (Figure 8 ). It is hypothesized that the PA modification facilitates strong uptake enhancement by preferentially accessing macropinocytotic pathways; this preferential uptake by macropinocytosis could be due to the larger size of the siRNA-PA NPs. Internalization via this pathway may also impact siRNA-PA NP intracellular retention and cytoplasmic bioavailability, as it is accepted that the endocytotic mechanism has a significant impact on the trafficking and ultimate intracellular fate of internalized therapeutics 51, 52 . For example, macropinosomes are believed to be leakier and to provide an easier access point into the cellular cytoplasm 52 , which may enhance the efficiency of endosomal escape and intracellular bioavailability of the siRNA-PA NPs. These uptake inhibitor data, combined with the belief that PA conjugation improves siRNA resistance to degradation 20 , motivated investigation of intracellular retention ( Figure 7) and longevity of gene silencing ( Figure 9 ). Both of these studies suggested significantly greater persistence for siRNA-PA NPs relative to siRNA NPs. This effect is anticipated to be impactful for regenerative applications where repeat administration of siRNA may not be convenient or feasible.
In conclusion, these studies indicated that siRNA conjugation to PA acts synergistically with endosomolytic polymer NP formulations. PA conjugation reduced the required ratio of polymer:siRNA and improved silencing potency, which was relevant across multiple genes and 25 cell types relevant to tissue regeneration. Ultimately, the siRNA-PA would significantly reduce the ratio of polymer:siRNA as well as the overall dose of siRNA necessary for functional gene silencing. Furthermore, PA conjugation significantly improved longevity of silencing of siRNA.
Thus, utilization of siRNA-PA NPs would facilitate a sustained functional effect with less frequent and/or lower doses, effectively broadening the therapeutic index and enhancing the probability of success for siRNA applications in tissue engineering.
Future Work
Ongoing work concentrates on verifying the gene silencing and functional efficacy of the siRNA-PA nanoparticle system for local delivery via biomaterial scaffolds in vivo. This will be evaluated in a mouse subcutaneous implant model, which our lab has previously validated 25 .
Future studies will also investigate the potential for siRNA conjugates to elicit local gene silencing effects without the use of a nanocarrier system. 
